BioNTech SE
22UA.F
XETRA
96.75
EUR-0.65(-0.67%)
As of today
BioNTech SE fundamentals
22UA.F Income Statement
| Period Ending | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 61,598,000 | 127,575,000 | 108,589,000 | 482,325,000 | 18,976,700,000 | 17,310,600,000 | 3,819,000,000 | 2,751,100,000 | |
| Cost of Revenue | 94,814,000 | 156,730,000 | 243,827,000 | 704,362,000 | 3,860,700,000 | 4,532,000,000 | 599,800,000 | 541,300,000 | |
| Gross Profit | -33,216,000 | -29,155,000 | -135,238,000 | -222,037,000 | 15,116,000,000 | 12,778,600,000 | 3,219,200,000 | 2,209,800,000 | |
| Gross Profit Margin | -0.539 | -0.229 | -1.245 | -0.46 | 0.797 | 0.738 | 0.843 | 0.803 | |
| R&D Expenses | 85,496,000 | 143,040,000 | 226,466,000 | 645,029,000 | 952,851,491 | 1,460,905,854 | 1,783,100,000 | 2,254,200,000 | |
| General & Administrative Expenses | 22,889,000 | 24,049,000 | 40,692,000 | 94,049,000 | 278,500,000 | 484,700,000 | 495,000,000 | 531,100,000 | |
| Selling & Marketing Expenses | 6,603,000 | 3,041,000 | 2,718,000 | 14,512,000 | 50,400,000 | 59,500,000 | 62,700,000 | 67,900,000 | |
| SG&A Expenses | 29,492,000 | 27,090,000 | 43,410,000 | 108,561,000 | 328,900,000 | 544,200,000 | 557,700,000 | 599,000,000 | |
| Other Expenses | -86,927,000 | -145,432,000 | -223,596,000 | -893,210,000 | -128,800,000 | -408,300,000 | 188,000,000 | 670,900,000 | |
| Total Operating Expenses | 28,061,000 | 24,698,000 | 46,280,000 | -139,620,000 | 200,100,000 | 135,900,000 | 2,528,800,000 | 3,524,100,000 | |
| Total Costs & Expenses | 122,875,000 | 181,428,000 | 290,107,000 | 564,742,000 | 4,060,800,000 | 4,667,900,000 | 3,128,600,000 | 4,065,400,000 | |
| Interest Income | 2,003,567 | 2,059,905 | 1,775,842 | 1,564,000 | 1,559,835 | 48,500,000 | 350,269,936 | 437,600,000 | |
| Interest Expense | 634,979 | 1,776,100 | 1,713,024 | 64,949,000 | 5,615,407 | 18,900,000 | 569,936 | 12,600,000 | |
| Depreciation & Amortization | 9,852,517 | 22,687,856 | 33,797,834 | 36,097,562 | 78,199,751 | 121,079,311 | 183,400,000 | 298,000,000 | |
| EBITDA | -70,131,439 | -24,637,332 | -143,409,465 | -97,894,980 | 15,730,420,718 | 12,857,778,376 | 1,087,600,000 | -367,100,000 | |
| EBITDA Margin | -1.139 | -0.193 | -1.321 | -0.203 | 0.829 | 0.743 | 0.285 | -0.133 | |
| Operating Income | -61,277,000 | -53,854,000 | -181,518,000 | -82,417,000 | 15,283,800,000 | 12,642,700,000 | 690,400,000 | -1,314,300,000 | |
| Operating Income Margin | -0.995 | -0.422 | -1.672 | -0.171 | 0.805 | 0.73 | 0.181 | -0.478 | |
| Total Other Income/Expenses (Net) | -24,628,000 | 6,192,000 | 2,100,000 | -63,400,000 | -237,400,000 | 311,400,000 | 495,700,000 | 636,600,000 | |
| Income Before Tax | -85,905,000 | -47,662,000 | -179,440,000 | -145,802,000 | 15,046,400,000 | 12,954,100,000 | 1,186,100,000 | -677,700,000 | |
| Pre-Tax Income Margin | -1.395 | -0.374 | -1.652 | -0.302 | 0.793 | 0.748 | 0.311 | -0.246 | |
| Income Tax Expense | 45,000 | 600,000 | -268,000 | -161,000,000 | 4,753,900,000 | 3,519,700,000 | 255,800,000 | -12,400,000 | |
| Net Income | -85,653,000 | -48,019,000 | -179,172,000 | 15,200,000 | 10,292,500,000 | 9,434,400,000 | 930,300,000 | -665,300,000 | |
| Net Income Margin | -1.391 | -0.376 | -1.65 | 0.032 | 0.542 | 0.545 | 0.244 | -0.242 | |
| Earnings Per Share (EPS) | -0.38 | -0.21 | -0.85 | 0.06 | 43.87 | 38.08 | 3.87 | -2.77 | |
| Diluted Earnings Per Share (EPS) | -0.38 | -0.21 | -0.85 | 0.057 | 41.21 | 37.09 | 3.83 | -2.77 | |
| Weighted Average Shares Outstanding | 226,859,216 | 226,859,216 | 211,499,000 | 235,442,000 | 244,000,000 | 243,300,000 | 240,600,000 | 240,400,000 | |
| Weighted Average Shares Outstanding (Diluted) | 226,859,216 | 226,859,216 | 211,499,000 | 248,527,000 | 259,700,000 | 249,800,000 | 242,700,000 | 240,400,000 |